Vascular, hemodynamic and renal effects of low‐dose losartan in rats with secondary biliary cirrhosis
- 20 May 2005
- journal article
- Published by Wiley in Liver International
- Vol. 25 (3) , 657-666
Abstract
Background: In cirrhosis, splanchnic and systemic vasodilatation induce a hyperdynamic circulatory dysfunction, portal hypertension and renal sodium retention. This vasodilatation is in part because of an impaired vascular response to α1‐adrenoceptor agonists. Recently, the angiotensin II type 1‐receptor antagonist losartan has been shown to attenuate portal hypertension. We hypothesized that losartan decreases portal pressure by counteracting the impaired vascular responsive to α1‐adrenoceptor agonists.Methods: We studied, in rats with secondary biliary cirrhosis and sham‐operated rats, the effect of 0.5 and 10 mg losartan/kg × day on aortic responsiveness to α1‐adrenoceptor stimulation with methoxamine and angiotensin II (myograph), splanchnic and systemic hemodynamics (colored microspheres), plasma noradrenaline levels and kidney function.Results: In cirrhotic rats, 10 mg losartan/kg × day completely inhibited aortic contractility to angiotensin II, decreased vascular resistance and arterial pressure and induced renal failure. In contrast, 0.5 mg losartan/kg × day only partially inhibited aortic contractility to angiotensin II, but improved aortic contractility to methoxamine, increased splanchnic and systemic vascular resistance, decreased portal pressure, decreased plasma norepinephrine levels and induced natriuresis.Conclusions: In cirrhotic rats, losartan at a very low dose increases splanchnic vascular resistance, decreases portal pressure and improves kidney function, possibly by an increased vascular responsiveness to α1‐adrenoceptor agonists.Keywords
This publication has 31 references indexed in Scilit:
- Acute haemodynamic effects of losartan in anaesthetized cirrhotic ratsEuropean Journal of Clinical Investigation, 2003
- Contractile hyporesponsiveness of hepatic arteries in humans with cirrhosis: Evidence for a receptor-specific mechanismHepatology, 2001
- Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertensionGastroenterology, 2001
- Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosisGastroenterology, 2001
- Effect of Losartan, An Angiotensin Ii Receptor Antagonist, on Portal Pressure in CirrhosisHepatology, 1999
- Altered adrenergic responsiveness of endothelium-denuded hepatic arteries and portal veins in patients with cirrhosisGastroenterology, 1999
- In Vitro Evidence for Vascular Hyporesponsiveness in Clinical and Experimental CirrhosisPharmacology & Therapeutics, 1997
- The role of increased nitric oxide in the vascular hyporeactivity to noradrenaline in long-term portal vein ligated ratsJournal of Hepatology, 1995
- Elevated plasma norepinephrine concentrations in decompensated cirrhosis. Association with increased secretion rates, normal clearance rates, and suppressibility by central blood volume expansion.Circulation Research, 1985
- Circulatory changes in chronic liver diseaseThe American Journal of Medicine, 1958